ESMO/LinkedIn
Jun 29, 2024, 06:16
Microbiome Research is reshaping colorectal cancer treatment
ESMO shared on LinkedIn:
“ESMOGI24: Since the development of Colorectal Cancer (CRC) is intertwined with the gut microbiome, lessons learned about the importance of its composition in immune checkpoint inhibitor therapy response could be crucial in tailoring cancer care.
Being able to identify the patients with poor gut microbiota composition provides clinicians with the opportunity to manipulate the microbiome and thereby potentially enhance their subsequent response to immunotherapy.
Read the ESMO Daily Reporter article to explore how advancing Microbiome Research is reshaping CRC treatment.”
Source: ESMO/LinkedIn
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 22, 2025, 13:57
Aug 22, 2025, 13:28
Aug 22, 2025, 13:23
Aug 22, 2025, 13:01
Aug 22, 2025, 12:44
Aug 22, 2025, 12:33